PeptMentor
CalculatorsHow we source
PeptMentor
PeptMentor
Peptides
Eloralintide
Retatrutide
GHK-Cu
Pinealon
KPV
KLOW
All peptides
Compared
Eloralintide vs cagrilintide
Eloralintide vs retatrutide
Retatrutide vs tirzepatide
Guides and tools
Bac water for peptides
How to reconstitute peptides
Peptide reconstitution calculator
All guides
About
How we source
About
Editorial policy
Open the peptide calculator
PeptMentor

Plain answers about peptides and GLP-1 medicines. Every figure links to its source and says what kind of study it came from.

No dose advice. No sponsors, sellers or affiliate codes.

Peptides

  • Eloralintide
  • GHK-Cu
  • KLOW
  • KPV
  • Pinealon
  • Retatrutide
  • All peptides

Compare

  • Eloralintide vs cagrilintide
  • Eloralintide vs retatrutide
  • Retatrutide vs tirzepatide

Guides and tools

  • Peptide reconstitution calculator
  • Bac water for peptides
  • How to reconstitute peptides
  • All guides

About us

  • About
  • How we check facts
  • Editorial policy
  • Sources
  • Contact
© 2026 PeptMentor LLC. For information only, not medical advice. In an emergency call 911.
Medical disclaimerTermsPrivacyConsumer health data
  1. /Home
  2. /Peptides
  3. /Eloralintide

Weekly shot · weight loss · in phase 3 trials

Eloralintide: trial results and side effects

A weekly shot that helped people in a trial lose about a fifth of their weight. It is not approved anywhere yet. Whether you are curious, in a trial, or already on it, here is what helps.

A man preparing a simple breakfast of yoghurt and fruit
StatusIn trials, not approved
How sure is science?Large trials in people
Biggest trial result−20.1% vs −0.4% placebo, 48 weeks
Most common side effectsNausea and tiredness, more on higher doses

Status as of November 17, 2026. For information only, not medical advice: read the medical disclaimer.

Where are you with Eloralintide?

Before you decide

Good place to start. Here is what we would want to know before deciding, in plain words.

It is not approved yet

Eloralintide is still in trials. The only legal way to get it is to join a trial. The first big phase 3 trial is not expected to finish before 2028, so there is no launch date.

Status and the law →

What it did in trials

In the main trial, people on 9 mg lost about a fifth of their weight over 48 weeks. People on placebo lost almost nothing (0.4%).

Human randomised trialTrial results →

What it felt like

On 9 mg, about 1 in 3 felt sick (1 in 7 on placebo) and about 4 in 10 felt tired (1 in 8 on placebo). On the lowest two doses, nausea was about as common as on placebo.

Side effects explained →

A mood signal to know about

In one small study, 4 people had low mood. The 3 who stopped the drug felt better within 2 to 4 days. Larger trials have not yet said whether this happens more than on placebo.

What the study found →

Take these questions to your doctor

  • Is there an eloralintide trial I could join near me?
  • Would I be on the drug or on placebo, and would I know?
  • I take tirzepatide or semaglutide now. Can I join a trial while on it?
  • Could any of my medicines interact with it?
  • What should I do if I feel low or my mood changes?

Coming Pick your questions and print them as one page.

Your first weeks

Eloralintide has no label, so there are no official rules for starting it. Here is what the trials saw, and what the label of a different approved drug advises.

In a trial, the team sets the dose

There is no approved eloralintide dose. If you join a trial, the trial team decides your dose and how it changes. The doses on this page are what the trials tested, not a plan for you.

Every trial arm →

Stomach effects came early

In trials, stomach side effects happened mainly while doses were being raised. In phase 2, raising the dose more slowly meant fewer stomach effects and less tiredness. This describes the trials, not a plan for you.

What the trials saw →

Small habits from a label

  • Never share pens or needles, even with a new needle.
  • Tell every provider you are on it before any surgery.
Source: Zepbound Medication Guide, a different approved drug[1]

Write down your starting point

Weight, waist and a photo on day one make it much easier to see change later.

Coming A progress log that stays only on your device.

Living with it

You’re on it. Here’s how to feel better day to day, and how to tell if it’s working.

If your stomach is upset

  • Drink fluids. Losing fluid through sickness or diarrhoea can harm your kidneys.
  • Tell your provider if it is severe or will not go away.
Source: Zepbound Medication Guide[1]

Feeling tired?

Tiredness was one of the side effects that rose most with dose in phase 2, in up to about 46% of people on some doses (12% on placebo). Mention it to your doctor or trial team.

The trial numbers →

Keep an eye on your mood

Because of the small mood signal in early trials, note how you feel each week. If you feel low, tell your doctor or trial team. No judgement, it is useful for them to know.

About the mood signal →

Is it working?

We have not seen a week-by-week weight curve from the main trial, only the result at week 48.

  • Look at your weekly average weight, not one day.
  • Measure your waist once a week, at the same spot.
  • Note side effects: what, when, how bad, how long. Include changes in mood.

Got it outside a trial? Lower the risk.

No judgement. We won’t tell you where to buy or how much to take. Trial results describe Lilly’s study drug, not products sold online under the same name. No trial has tested those in people, so nobody knows what to expect. These steps lower the risk whatever you use:

  • Use clean technique every time. Our guide on how to reconstitute peptides covers the basics.
  • Never share pens, needles or vials.
  • Tell your doctor what you are taking, even if it feels awkward. It changes what they watch for.
  • Report a bad reaction to the FDA’s MedWatch[2]. It helps everyone.
Source: FDA MedWatch[2]

When to get help

Most side effects are mild and fade. A few need a call today, and a few need help right now. Here is how to tell them apart.

Emergency: call 911 (or your local emergency number). Possible overdose or wrong amount: Poison Help, 1-800-222-1222, free and open 24 hours. Report a bad reaction to the FDA through MedWatch.

Get emergency help now if you have

  • Swelling of your face, lips, tongue or throat, or problems breathing or swallowing.
  • A severe rash or itching, fainting or feeling dizzy, or a very fast heartbeat.
Source: serious side effects in the Zepbound Medication Guide, a different approved drug[1]

Call your doctor today if you have

  • Nausea, vomiting or diarrhoea that does not go away.
  • Pain in your upper belly, fever, yellow skin or eyes, or clay-coloured stools (gallbladder).
  • Severe belly pain that will not go away, with or without vomiting. You may feel it from your belly to your back (pancreas).
Source: Zepbound Medication Guide[1]

Feeling low or not yourself?

Tell your doctor or trial team soon. In a small study, people whose mood dropped felt better within 2 to 4 days of stopping the drug.

The mood findings →

Usually not urgent, but worth mentioning

  • Mild sickness, tiredness or a smaller appetite, often while the dose is going up.
  • Headaches.
  • A slower resting pulse. In a 12-week study it fell with dose, and no one had a slow heart rate that caused symptoms.

The science, if you want it

Every number below says what kind of study it came from. Bracketed numbers point to the sources listed at the end.

Human RCT (phase 2)Phase 3 running · not approved
CellAnimalSmall humanHuman randomised trialApproved

Best evidence: human randomised trial

Facts checked 2026-11-17 · by PeptMentor Team · How we source

On this page
Eloralintide at a glanceWhat the trials saw, week by weekLiving with it day to daySide effects: what's common, what helps, when to callIs it working? How to track itYour appointment checklistWhat is eloralintide?How eloralintide worksWhat the eloralintide trials foundEloralintide doses studied in trialsEloralintide side effects reported in trialsPhase 3 trials and timelineIs eloralintide approved or legal?How eloralintide comparesEloralintide: questions people askSources

Eloralintide at a glance

Key takeaways
  • Eloralintide is a weekly shot that is still in trials. It is not approved anywhere, and you can only get it legally in a trial.Company press releaseLilly press release, 2026-11-14
  • In the main trial, people on 9 mg lost about one fifth of their body weight in 48 weeks. People on placebo lost almost nothing (20.1% vs 0.4%).Human randomised trial[3]
  • Nausea and tiredness were the side effects that went up most with dose. On the lowest two doses, nausea was about as common as on placebo.Human randomised trial[3]
  • In one small study, 4 people had low mood. The 3 who stopped the drug felt better within 2 to 4 days.Small human study[4]
  • The big phase 3 trials will not finish before 2028, so there is no launch date.Trial registry[5]
I'm…just curiousworried about a side effectalready on tirzepatidewaiting for it to launch

What the trials saw, week by week

Eloralintide trials, by time point
  1. Days 3 to 6 after a shotPMID 41109426
    Blood levels peak

    After one shot, the drug reached its highest level in the blood 72 to 132 hours later. With weekly shots, levels stayed fairly even through the week[4].

    Small human study[6]
  2. Week 4PMID 41109426
    A small drop after one shot

    In healthy adults given a single 12 mg shot, weight was down 4.4% four weeks later. On placebo it went up 0.6%.

    Small human study[6]
  3. Week 12PMID 41559929
    Weekly shots, no step-up

    In a study of 100 adults, the 12 mg group lost 11.3% more than placebo after 12 weeks. About 1 in 5 people on the drug had less appetite (19%), and about 1 in 8 had headaches (12%).

    Small human study[4]
  4. While the dose goes upLilly press release, 2026-09-30
    When stomach effects showed up

    In a trial with tirzepatide, stomach side effects happened mainly while doses were being raised. In phase 2, raising the dose more slowly meant fewer stomach effects and less tiredness (Lilly release, 2025-11-06).

    Company press releaseLilly press release, 2026-09-30
  5. Week 48PMID 41207310
    About one fifth of body weight

    In the main trial, the 9 mg group lost 20.1% of their weight on average, about 21 kg. The placebo group lost 0.4%.

    Human randomised trial[3]

Averages from trials, not a forecast for you. Each step comes from a different trial with different people and doses, so the steps are not one curve. Sources: days 3 to 6 and week 4[6]; levels through the week and week 12[4]; step-up, Lilly releases 2025-11-06 and 2026-09-30; week 48[3] and Lilly release 2025-11-06.

We have not seen a week-by-week weight curve from the phase 2 trial, only the result at week 48. The full paper may have one; we have read only the abstract.

Living with it day to day

Eloralintide has no label yet
Approved drugs come with a label that covers storage, travel, food and missed doses. Eloralintide has none, so there are no official rules for it. Every multiple-dose trial so far gave it as a shot under the skin once a week.

What people in the trial said. In exit interviews from phase 2, 74% said they had fewer cravings and 52% said they had less "food noise". Of those who drank alcohol at the start, 41% said they drank less (Lilly release, 2026-11-14). Lilly did not say how many people were interviewed.

We have not added advice on what to eat when your appetite drops. We will only add it from published guidance, with the source named.

Side effects: what's common, what helps, when to call

In phase 2, on 9 mg about 1 in 3 people had nausea, vs about 1 in 7 on placebo (33% vs 14%). About 4 in 10 felt tired, vs about 1 in 8 on placebo (43% vs 12%). On 6 mg, about 2 in 3 had nausea (64%). On 1 mg and 3 mg, nausea was about as common as on placebo (11% and 13%). Source: Lancet 2025[3]; full tables in side effects reported in trials.

Mood. In the 12-week phase 1b study, 3 people had low mood and 1 had a longer-lasting low mood. The 3 on 12 mg stopped the drug, and their mood got better within 2 to 4 days[4]. Larger trials have not yet said whether this happens more often than on placebo.

What the Zepbound Medication Guide says
  1. Drink fluids

    Diarrhoea, nausea and vomiting can make you lose fluids. The guide says drinking fluids helps lower the chance of dehydration, which can harm your kidneys.

  2. Speak up if it won't go away

    The guide says to tell your provider about stomach problems that are severe or will not go away.

  3. Never share pens or needles

    The guide says not to share a pen or needles, even with a new needle. You could pass on or catch a serious infection.

  4. Tell every provider before surgery

    The guide says food can get into the lungs during procedures that put you to sleep. Tell all your providers before any surgery.

These tips come from the Zepbound (tirzepatide) Medication Guide[1], revised 08/2026. Tirzepatide is an approved weight-loss medicine that works on different hormones, and Lilly is testing it together with eloralintide. Eloralintide has no label of its own, and no study has tested these tips with eloralintide. Nothing here is advice to change a dose.

These warning signs come from the Zepbound (tirzepatide) Medication Guide[1], revised 08/2026, the label of an approved medicine that works differently. Eloralintide has no label of its own, so these are not eloralintide warnings.

Call your doctor or prescriber today if
  • Stomach problems that are severe or will not go away.
  • Nausea, vomiting or diarrhoea that does not go away.
  • Pain in your upper belly, fever, yellow skin or eyes, or clay-colored stools. These can be signs of gallbladder problems.
  • Severe belly pain that will not go away, with or without vomiting. You may feel it from your belly to your back. This can be a sign of an inflamed pancreas.
Get emergency help now if
  • Swelling of your face, lips, tongue or throat.
  • Problems breathing or swallowing.
  • A severe rash or itching, fainting or feeling dizzy, or a very fast heartbeat.

Is it working? How to track it

Simple things to track
  • Weigh yourself at the same time of day. Look at the weekly average, not one day.
  • Measure your waist once a week, at the same spot.
  • Take photos in the same light and the same clothes.
  • Notice how your clothes fit.
  • Note any side effects: what, when, how bad and how long. Include changes in mood.

These are ways to keep a record. They are not targets, and they do not replace checks by your doctor or trial team.

Your appointment checklist

Bring these to your appointment
  • Is there an eloralintide trial I could join near me?
  • Would I be on the drug or on placebo, and would I know?
  • What dose would I start on, and how would it go up?
  • I take tirzepatide or semaglutide now. Can I join a trial while on it?
  • Could any of my medicines interact with it?
  • What should I do if I feel low or my mood changes?
  • What should I do if side effects do not ease?

Dose questions belong with your prescriber or trial team. This page lists trial doses only, and none of them is a dose for you.

What is eloralintide?

An amylin copy built to last: structure, other names and a 13 to 15 day half-life.

Eloralintide is a long-acting amylin receptor agonist developed by Eli Lilly under the code name LY3841136[6]. It is given as a once-weekly injection under the skin in trials. It is investigational: Lilly calls it investigational (Lilly press release, 2026-11-14), and phase 3 trials started in December 2025[5].

−20.1%

Mean weight change, 9 mg, 48 weeks, phase 2 (efficacy estimand)[3]

Human randomised trial
12.9–15.3 days

Half-life after a single dose (310 to 366 hours)[6]

Small human study
8

Phase 3 trials registered, about 11,730 people planned (ClinicalTrials.gov, 2026-11-17)

Trial registry
2028-01

Earliest estimated phase 3 primary completion (ENLIGHTEN-2)[5]

Trial registry
Best evidence so far
CellAnimalSmall humanHuman randomised trialApproved

Best evidence: human randomised trial

Highest rung reached: a phase 2 human RCT (Lancet 2025). Eight phase 3 trials are running and none has reported.

Elora, LY3841136 and misspellings. "Elora" and "Elora peptide" are community short names for eloralintide. LY3841136 is Lilly's code name. "Eloranlintide" and "loralintide" are common misspellings of the same drug.

Structure in plain words. Eloralintide is a modified copy of the hormone amylin. Its main chain has 37 amino acids, three of which are not found in natural proteins. A more stable chemical bridge replaces the natural amylin's sulphur bridge, and a fatty acid is attached at position 26 so that the drug binds to albumin in the blood, which makes it last longer (full text PMC12640043)[6].

Half-life. After a single dose, the half-life was 310 to 366 hours (12.9 to 15.3 days) across doses from 0.04 to 12 mg, and blood levels peaked 72 to 132 hours after the injection[6]. With weekly dosing, the ratio between peak and trough levels at steady state was 1.28 to 1.38, meaning levels stayed fairly even through the week[4].

How eloralintide works

Amylin receptors, and which findings come from cells, rats or people.

Amylin is released from the pancreas together with insulin. It slows stomach emptying, lowers glucagon and acts on the brain to bring on fullness[7]. Eloralintide is built to act mainly on one amylin receptor, called AMY1R. The table shows which findings come from cells, animals or people.

FindingWhere it was shownSource
Activates the human AMY1R receptor 12 times more than the calcitonin receptor and 11 times more than AMY3RCells[6]
In rat cells the pattern differs: AMY1R and AMY3R were both activated more than the calcitonin receptorCells (rat)[6]
Less taste avoidance (an animal sign of feeling unwell) than cagrilintide, p < 0.05, in a Lilly-run studyLean rats[6]
Lower food intake and body weight, mostly from fat lossRats with diet-induced obesity[6]
Weight loss that grows with dosePeople: phase 1 and phase 2 trials[3]

Reviewers suggest that acting mainly on the amylin receptor, and less on the calcitonin receptor, may affect how well the drug is tolerated. This is a hypothesis; no human trial has tested it[8]. Because receptor selectivity differs between rats and people, rat results cannot be carried straight over to humans.

What the eloralintide trials found

Phase 1, 1b, 2 and the EloraTZP phase 2b results, arm by arm.

Phase 1, single doses. In 48 healthy adults given one dose of 0.04 to 12 mg, weight four weeks later had changed by −2.5% on 4 mg and −4.4% on 12 mg, vs +0.6% on placebo[6][9].

Phase 1b, 12 weeks of weekly doses. In 100 adults with overweight or obesity, doses were given at a fixed level with no step-up. Weight change vs placebo at week 12 was −2.6% (1.2 mg), −8.9% (3 mg), −8.5% (6 mg) and −11.3% (12 mg)[4].

Phase 2, 48 weeks, 263 people. The main trial enrolled adults with a BMI of 30 or more, or 27 or more with a weight-related condition, and no type 2 diabetes, at 46 US sites. Average starting weight was 109.1 kg[3][10]. The weight figures below use the efficacy estimand, which assumes everyone stayed on treatment. The figure that counts people who stopped (treatment-regimen estimand) is in the full paper, which we have not yet read.

Arm (once weekly)nWeight change at 48 weeks95% CINauseaFatigue
1 mg28−9.5%−12.6 to −6.311%0%
3 mg24−12.4%−14.9 to −9.813%13%
6 mg28−17.6%−20.7 to −14.564%29%
9 mg54−20.1%−22.7 to −17.533%43%
6 → 9 mg24−19.9%−22.7 to −17.054%46%
3 → 6 → 9 mg52−16.4%−18.6 to −14.125%21%
Placebo53−0.4%−2.2 to 1.414%12%

Weight change: exact values from Lilly's release (2025-11-06); 95% confidence intervals from the Lancet abstract[3], which rounds the means. Nausea and fatigue: Lancet abstract. Efficacy estimand.

Phase 2: mean weight loss at 48 weeks (%, efficacy estimand)

Scale: 0–20.1%

1 mg9.5%
3 mg12.4%
6 mg17.6%
9 mg20.1%
6 → 9 mg19.9%
3 → 6 → 9 mg16.4%
Placebo0.4%

Bars show weight lost. Source: Lancet 2025[3]; exact values from Lilly's release, 2025-11-06. On 9 mg the mean loss was 21.3 kg vs 0.2 kg on placebo (Lilly release).

Who ran the trials. All published eloralintide trials were funded by Lilly. In the phase 1 paper, every author was a Lilly employee[6].

Phase 2b with tirzepatide (EloraTZP). Lilly tested eloralintide alone and together with tirzepatide (given as separate injections) in 367 people with obesity and type 2 diabetes for 48 weeks. The results come from a company press release (2026-09-30, presented at EASD) and had not appeared in a journal by 2026-11-17[11].

ArmWeight changeHbA1c change (points)
Eloralintide 3 mg + tirzepatide 5 mg−13.2%−2.2
Eloralintide 6 mg + tirzepatide 5 mg−19.4%−2.7
Eloralintide 6 mg + tirzepatide 10 mg−19.9%−2.6
Eloralintide 9 mg + tirzepatide 15 mg−23.3%−2.9
Tirzepatide 15 mg alone−14.8%−2.4
Eloralintide 3 mg alone−8.2%−1.1
Eloralintide 6 mg alone−12.3%−1.4
Eloralintide 9 mg alone−11.1%−1.3
Placebo−3.0%−0.3

EloraTZP phase 2b, 48 weeks, efficacy estimand. Source: Lilly press release, 2026-09-30 (company press release, not peer-reviewed); trial record[11].

What people in phase 2 said afterwards. In exit interviews from the phase 2 trial, 74% reported fewer cravings, 52% reported less "food noise", and 41% of those who drank alcohol at the start said they drank less (Lilly press release, 2026-11-14, ObesityWeek poster). These are company-reported qualitative interviews, and Lilly did not say how many people were interviewed.

What independent reviews say. A network meta-analysis of six trials (4,642 people) estimated −18.01% vs placebo for high-dose eloralintide. The authors call the evidence sparse and low-certainty, and the comparison is across trials of different lengths[12]. A narrative review describes its early side-effect profile, including fatigue, headache and loss of appetite, as distinct from other drugs in the class[13].

Eloralintide doses studied in trials

Every trial arm studied so far. Not a dosing guide.
These are trial arms, not doses to use
There is no approved eloralintide product, label or dose. Each row is a published trial arm: what was tested and what happened.
Published trial arms
Trial and sourceDose tested and how it was reachedWeeksWeight change
Phase 1 single doseSmall human study[6]One dose: 0.04, 0.12, 0.4, 1.2, 4 or 12 mgHealthy adults, n=484 (follow-up)4 mg −2.5%; 12 mg −4.4% vs placebo +0.6%
Phase 1bSmall human study[4]1.2 mgNo escalation12−2.6% vs placebo
Phase 1bSmall human study[4]3 mgNo escalation12−8.9% vs placebo
Phase 1bSmall human study[4]6 mgNo escalation12−8.5% vs placebo
Phase 1bSmall human study[4]12 mgNo escalation12−11.3% vs placebo
Phase 2Human randomised trial[3]1 mgFixed48−9.5%
Phase 2Human randomised trial[3]3 mgFixed48−12.4%
Phase 2Human randomised trial[3]6 mgFixed48−17.6%
Phase 2Human randomised trial[3]9 mgFixed48−20.1%
Phase 2Human randomised trial[3]9 mg6 → 9 mg48−19.9%
Phase 2Human randomised trial[3]9 mg3 → 6 → 9 mg48−16.4%
Phase 2Human randomised trial[3]Placebo–48−0.4%
Phase 2b (T2D)Company press releaseLilly 2026-09-30 ·[11]3 / 6 / 9 mg aloneNot stated in the release48−8.2 / −12.3 / −11.1%
Phase 2b (T2D)Company press releaseLilly 2026-09-30 ·[11]3 to 9 mg + tirzepatide 5 to 15 mg (4 pairings)Separate injections48−13.2% to −23.3%
Phase 3 (8 trials)Trial registryand others[14]Doses hidden in the registry as "Dose 1" to "Dose 4"Not public64 to 100No results yet

All arms were once weekly, under the skin, except the single-dose phase 1 study. Phase 1b figures are placebo-adjusted; phase 2 and 2b figures use the efficacy estimand.

How many weeks each step lasted in the 6 → 9 mg and 3 → 6 → 9 mg arms is not given in the Lancet abstract or Lilly's release. There is no eloralintide "protocol" to follow; the only sourced doses are the trial arms above. Every multiple-dose trial so far gave eloralintide once a week.

This page has no vial calculator, because no eloralintide product, label or vial size exists to measure.

Eloralintide side effects reported in trials

Nausea and fatigue by arm, mood events, pulse and who stopped.

In phase 2, nausea and tiredness were the side effects that changed most with dose. Lilly says stomach and gut side effects and fatigue were more frequent at higher doses, lower with slower step-up, and similar to placebo on 1 mg and 3 mg (Lilly press release, 2025-11-06).

Phase 2: nausea by arm vs placebo (% of people) Eloralintide Placebo

Scale: 0–64%

1 mg11% vs 14%
3 mg13% vs 14%
6 mg64% vs 14%
9 mg33% vs 14%
6 → 9 mg54% vs 14%
3 → 6 → 9 mg25% vs 14%

Source: Lancet 2025[3]. Placebo is the same 14% on every row. Fatigue figures are in the phase 2 table above (0% to 46% vs 12% on placebo).

Phase 1b side effects. Over 12 weeks, people on eloralintide reported less appetite (19%), headache (12%), fatigue (11%), diarrhoea (10%), nausea (8%) and vomiting (4%); 13% had injection-site reactions[4]. In the single-dose study, two people reported four stomach and gut events, one of them moderate vomiting[6].

Mood events in the phase 1b study. One person on 6 mg and two on 12 mg reported depressed mood, and one more on 12 mg had persistent depressive disorder. All three people on 12 mg with mood events stopped the drug, and the events resolved within 2 to 4 days[4]. The phase 2 abstract does not mention mood events, so it is not yet known whether this appears in larger trials.

Phase 1b: fall in pulse rate after 12 weeks

Scale: 0–14.4 bpm decrease

Placebo−3.4 bpm decrease
3 mg−7.1 bpm decrease
6 mg−8.3 bpm decrease
12 mg−14.4 bpm decrease

Bars show how far average pulse fell. The paper reports no slow heart rate that caused symptoms. Source: Bhattachar 2026[4].

TrialEloralintideComparatorSource
Phase 1b11 people: 5 COVID-19, 2 depressed mood, 1 each persistent depressive disorder, jaw fracture, sleepiness and decreased appetite; none for nausea, vomiting or diarrhoeaPlacebo: 2 (both COVID-19)[4]
Phase 2Not given in the abstract or release–[3]
Phase 2b (EloraTZP)Eloralintide alone 0% to 10.8%; with tirzepatide 10.8% to 27.0%Tirzepatide 2.9%; placebo 16.7% as reported (unusually high; not yet checked against a paper)Lilly 2026-09-30[11]

People who stopped because of side effects.

In the phase 2b trial, stomach and gut side effects were more frequent in the combination arms and happened mainly while doses were being stepped up (Lilly press release, 2026-09-30).

Searching "eloralintide reddit"? The figures on this page describe Lilly's study drug given under trial conditions. They tell you nothing about products sold online under the same name.

  • Rare side effects: trials so far are too small to show them.
  • Beyond 48 weeks: no safety data have been published.
  • Heart outcomes: no dedicated heart-outcomes trial exists yet, a gap a 2026 review points out[15].
  • Mood: whether the phase 1b mood signal recurs in larger trials.

Phase 3 trials and timeline

Eight phase 3 trials, about 11,730 people, earliest result 2028.
  1. 2022-03-30

    Phase 1b study of weekly doses begins at three US centres.

    Bhattachar et al., DOM 2026[4] Small human study
  2. 2024-02-05

    Phase 2 trial starts enrolling.

    Billings et al., Lancet 2025[3] Human randomised trial
  3. 2025-10-16

    Molecule and single-dose phase 1 results published.

    Briere et al., Mol Metab[6] Small human study
  4. 2025-11-06

    Phase 2 published in the Lancet: up to −20.1% at 48 weeks.

    Billings et al., Lancet[3] Human randomised trial
  5. 2025-12-15

    First phase 3 trial (ENLIGHTEN-2) starts.

    ClinicalTrials.gov[5] Trial registry
  6. 2026-02-06

    ENLIGHTEN-1 starts; ENLIGHTEN-3, -4 and -6 start the same month.

    ClinicalTrials.gov[14] Trial registry
  7. 2026-09-30

    EloraTZP phase 2b results announced at EASD.

    Lilly press release[11] Company press release
  8. 2026-10-16

    AMPLIFY-2 (EloraTZP vs tirzepatide) starts.

    ClinicalTrials.gov[16] Trial registry
  9. 2028-01

    Earliest estimated primary completion of a phase 3 trial (ENLIGHTEN-2).

    ClinicalTrials.gov[5] Trial registry
TrialRegistryWhoPeopleStartPrimary completionMain endpoint
ENLIGHTEN-1[14]Obesity or overweight, no diabetes1,9802026-02-062028-03Weight change, week 64
ENLIGHTEN-2[5]Obesity or overweight with type 2 diabetes1,0352025-12-152028-01Weight change, week 64
ENLIGHTEN-3[17]Moderate to severe sleep apnoea8002026-02-102028-03Weight change and AHI, week 64
ENLIGHTEN-4[18]Knee osteoarthritis pain9002026-02-092028-03Weight change and WOMAC pain, week 64
ENLIGHTEN-6[19]Obesity persisting on a weekly incretin drug; added on top9002026-02-102028-06Weight change, week 64
ENLIGHTEN-10[20]Obesity, type 2 diabetes and raised heart risk3,0002026-12 (planned)2029-11Weight change week 64; HbA1c week 36
AMPLIFY-1[21]Obesity, no diabetes: EloraTZP vs tirzepatide vs eloralintide vs placebo2,1152026-12 (planned)2029-10Weight change, week 100
AMPLIFY-2[16]Obesity with type 2 diabetes: EloraTZP vs tirzepatide1,0002026-10-162029-10Weight change, week 100

Read from ClinicalTrials.gov on 2026-11-17. None has posted results. Doses are hidden as "Dose 1" to "Dose 4". Dates are registry estimates.

Other registered studies have no published results yet, including phase 1 studies in Chinese[22] and Japanese participants[23], kidney and liver impairment studies[24][25], and phase 2 studies of macupatide with or without eloralintide[26][27].

Is eloralintide approved or legal?

Not approved anywhere. Compounding, warning letters and sport rules.

No. Eloralintide is not approved by the FDA or anywhere else; Lilly calls it investigational (Lilly press release, 2026-11-14). Lilly has not given a filing date in the sources we read. The only way to receive it legally is in a clinical trial.

ItemStatus as of 2026-11-17Source
FDA approvalNot approved; investigationalLilly press release, 2026-11-14
FDA 503A bulk substances categories listNot listed (searched the version updated 2026-05-14)FDA categories list[28]
HHS draft policy on 503A peptide compounding (2026-10-30)A draft notice with an appendix of peptides. We could not open the appendix; summaries by law firms list six peptides, and eloralintide is not one of themFederal Register, FR Doc 2026-22192[29]
FDA warning letters or import alerts naming eloralintideNone foundfda.gov search, 2026-11-17
Sport (WADA)Not named. It falls under S0, non-approved substances, which are prohibited at all timesWADA 2026 Prohibited List, section S0

How eloralintide compares

Cagrilintide (Novo Nordisk)

Both are amylin-based. Eloralintide acts mainly on AMY1R; cagrilintide also acts on the calcitonin receptor[6][30]. Eloralintide's single-dose half-life is 12.9 to 15.3 days; the same paper cites 6.6 to 8.1 days for cagrilintide. No human trial has compared them directly.

Retatrutide (Lilly)

Both are Lilly drugs in trials. Retatrutide acts on GIP, GLP-1 and glucagon receptors. Pulse fell with dose on eloralintide[4], while heart rate rose with dose on retatrutide[31]; these come from separate trials. No trial compares or combines the two.

With tirzepatide

Lilly's own combination, EloraTZP, is covered in the trial results above. AMPLIFY-1 will compare it with each drug alone over 100 weeks[21]. No combination of the two is approved.

Eloralintide vs cagrilintide →Two amylin drugs, different receptors and half-lives. No head-to-head trial.
Eloralintide vs retatrutide →An amylin agonist and a triple agonist, both from Lilly.
Retatrutide →Every trial arm, side effects and status.

Eloralintide: questions people ask

Direct answers to what people search for. Bracketed numbers point to the sources at the end; the sections above have the detail.

What is Elora? Is it a peptide?

"Elora" is a short name for eloralintide (code name LY3841136). It is a weekly shot from Eli Lilly, made as a changed copy of amylin, a hormone that helps you feel full[6].

Is eloralintide FDA approved?

No. Lilly calls it investigational, which means it is still being tested (Lilly release, 2026-11-14). It is in phase 3 trials.

When can I get eloralintide?

There is no date. Lilly has not given one in the sources we read. The first phase 3 trial is expected to reach its main result in January 2028[5].

How much weight could I lose on eloralintide?

No one can say for you. In the 48-week phase 2 trial, average weight change went from 9.5% lost on 1 mg to 20.1% lost on 9 mg. Placebo was 0.4% lost. These figures assume everyone stayed on the drug[3].

Would I take it every week?

Yes. Every trial with repeat doses gave it once a week as a shot under the skin. After one shot, the level in the blood took 12.9 to 15.3 days to drop by half[6].

Will eloralintide make me tired?

It might. In phase 2, tiredness went from 0% to 46% across the drug groups, vs 12% on placebo. It was more common on higher doses[3].

What is EloraTZP?

It is Lilly's mix of eloralintide and tirzepatide, given as two shots. In a 48-week trial in people with type 2 diabetes, the groups on both drugs lost 13.2% to 23.3% (Lilly release, 2026-09-30, not yet in a journal). Phase 3 trials have started[21].

Is eloralintide banned in sport?

Yes. WADA does not name it. But it has no approval anywhere, so it falls under section S0 of the 2026 Prohibited List. That section bans unapproved drugs at all times.

Sources

  1. 1.Zepbound Medication Guide, a different approved drug
  2. 2.MedWatch
  3. 3.Billings et al. 48-week phase 2 trial. Lancet 2025. PMID 41207310 Human randomised trial
  4. 4.Bhattachar et al. Phase 1b multiple-dose study. Diabetes Obes Metab 2026. PMID 41559929 Small human study
  5. 5.ENLIGHTEN-2, NCT07282600 Trial registry
  6. 6.Briere et al. Eloralintide discovery and phase 1 single-dose study. Mol Metab 2025. PMID 41109426 Small human study
  7. 7.review, PMID 42452898
  8. 8.review, PMID 42586227
  9. 9.Phase 1 trial record, NCT05295940 Trial registry
  10. 10.Phase 2 trial record, NCT06230523 Trial registry
  11. 11.EloraTZP phase 2b trial record, NCT06603571 Trial registry
  12. 12.Kamrul-Hasan 2026, PMID 42175595
  13. 13.Panou 2026, PMID 42803913
  14. 14.ENLIGHTEN-1, NCT07321886 Trial registry
  15. 15.PMID 42745233
  16. 16.ClinicalTrials.gov NCT07881458
  17. 17.NCT07369011
  18. 18.NCT07353931
  19. 19.NCT07392190
  20. 20.NCT07900633
  21. 21.AMPLIFY-1, NCT07881432 Trial registry
  22. 22.NCT06916091
  23. 23.NCT06297616
  24. 24.NCT07426380
  25. 25.NCT07401862
  26. 26.NCT07215559
  27. 27.NCT07589608
  28. 28.FDA 503A bulk drug substances categories list (updated 2026-05-14) Regulator
  29. 29.HHS draft enforcement-discretion policy, 503A peptide compounding. Federal Register, 2026-10-30 Regulator
  30. 30.review, PMID 41747885
  31. 31.PMID 37366315
On this pageEloralintide at a glanceWhat the trials saw, week by weekLiving with it day to daySide effects: what's common, what helps, when to callIs it working? How to track itYour appointment checklistWhat is eloralintide?How eloralintide worksWhat the eloralintide trials foundEloralintide doses studied in trialsEloralintide side effects reported in trialsPhase 3 trials and timelineIs eloralintide approved or legal?How eloralintide comparesEloralintide: questions people askSources